FR Doc E8-3858[Federal Register: February 29, 2008 (Volume
73, Number 41)] [Notices] [Page 11148-11149] From the Federal
Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29fe08-107]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing
a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
regulation under 21
U.S.C. 952(a)(2)(B) authorizing the importation
[[Page 11149]]
of such a substance, provide manufacturers holding
registrations for the bulk manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with Title
21 Code of Federal Regulations (CFR), 1301.34(a), this is
notice that on January 28, 2008, Meridian Medical Technologies,
2555 Hermelin Drive, St. Louis, Missouri 63144, made application
by renewal to the Drug Enforcement Administration (DEA) to be
registered as an importer of Morphine (9300), a basic class of
controlled substance listed in schedule II.
The company plans to import products for research
experimentation or clinical use and analytical testing.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of
controlled substance may file comments or objections to the
issuance of the proposed registration and may, at the same time,
file a written request for a hearing on such application
pursuant to 21
CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or objections being sent via
regular mail should be addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), Washington, DC 20537, or any
being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette Drive, Springfield,
Virginia 22152; and must be filed no later than March 31, 2008.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b),
(c), (d), (e) and (f). As noted in a previous notice published
in the Federal Register on September 23, 1975, (40 FR 43745-46),
all applicants for registration to import a basic class of any
controlled substance listed in schedule I or II are, and will
continue to be, required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration
pursuant to 21
U.S.C. 958(a), 21
U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E8-3858 Filed 2-28-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).